Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Chief Business Officer | July 02, 2024 | July 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date July 02, 2024 · Filed July 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33 |
Reported balance
After 2024-07-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-07-02 · Sale · Disposed 2,467 · Balance 33 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The shares sold in the reported transactions include an aggregate 2,500 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-07-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-07-02 · Sale · Disposed 33 · Balance 0 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The shares sold in the reported transactions include an aggregate 2,500 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2024 Filed Jul 3, 2024 20:13 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 33 | $13.90 | $458.70 |
DisclosureSEC source: 0001415889-24-019169 · form4-07032024_080758.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 20:13 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,467 | $13.10 | $32,320.17 |
DisclosureSEC source: 0001415889-24-019169 · form4-07032024_080758.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The shares sold in the reported transactions include an aggregate 2,500 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-24-014093 · form4-05222024_080503.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 50,000 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 50,000 | $15.39 | $769,500.00 |
DisclosureSEC source: 0001415889-24-014093 · form4-05222024_080503.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.91 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 20, 2024 Filed May 22, 2024 20:20 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 50,000 | $0.40 | $20,000.00 |
DisclosureSEC source: 0001415889-24-014093 · form4-05222024_080503.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001415889-24-009993 · form4-04032024_080414.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 50,000 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 400 | $13.61 | $5,444.00 |
DisclosureSEC source: 0001415889-24-009993 · form4-04032024_080414.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 60,929 | $13.22 | $805,767.75 |
DisclosureSEC source: 0001415889-24-009993 · form4-04032024_080414.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 400 F1 · kind: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.60 to $13.59 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:19 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 50,000 | $0.40 | $20,000.00 |
DisclosureSEC source: 0001415889-24-009993 · form4-04032024_080414.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2024 Filed Jun 7, 2024 20:41 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016008 · form4-06072024_080616.xml · derivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The award vests as to 1/4 of the total award annually beginning on March 15, 2025, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 27, 2024 Filed Jun 7, 2024 20:41 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0001415889-24-016008 · form4-06072024_080616.xml · derivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-03-26 F1 · derivative.exercise_date: The option vested or vests as to 1/48 of the total award on April 15, 2024, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 00:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 4,116 | $6.10 | $25,101.84 |
DisclosureSEC source: 0001415889-24-008686 · form4-03202024_120349.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,329 F2 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.94 to $6.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionRestricted Stock Units · Derivative | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008686 · form4-03202024_120349.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,300 Underlying: Common Stock · 13,100 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. F5 · derivative.exercise_date: The award vested or vests as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2024 Filed Mar 20, 2024 00:31 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 13,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008686 · form4-03202024_120349.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The reported total includes an aggregate 2,345 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unit (RSU) · Derivative | 8,463 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057403 · doc4.xml · derivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,463 Underlying: Common Stock · 8,463 shares Expires 2025-12-01 F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: 7,053 restricted stock units will vest on December 1, 2024 and 1,410 will vest on December 1, 2025, subject to the reporting person's continued service to the Issuer on each such date. Read SEC document |
| December 01, 2023 Filed Dec 5, 2023 21:17 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,600 | Not disclosed Strike: $60.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-057403 · doc4.xml · derivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,600 shares Expires 2031-03-01 F2 · price: On December 1, 2023, the Issuer cancelled, pursuant to the Issuer's option exchange program, options to purchase 65,600 shares of Common Stock of the Issuer and in exchange issued to the reporting person 8,463 restricted stock units. F1 · derivative.exercise_date: The canceled option vested as to 1/48th of the total award on April 2, 2021 and provided for 1/48th of the total award to vest monthly thereafter, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantRestricted Stock Unit (RSU) · Derivative | 52,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-019656 · doc4.xml · derivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,400 Underlying: Common Stock · 52,400 shares Expires 2027-03-15 F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F3 · derivative.exercise_date: The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:33 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 78,600 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001209191-23-019656 · doc4.xml · derivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,600 Underlying: Common Stock · 78,600 shares Expires 2033-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 22:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001209191-22-060546 · doc4.xml · derivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2032-12-06 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on January 7, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 21:13 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 107,400 | $0.00 Strike: $20.34 | $0.00 |
DisclosureSEC source: 0001209191-22-019684 · doc4.xml · derivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 107,400 shares Expires 2032-03-14 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 15, 2022 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,800 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-22-001849 · doc4.xml · derivative · entry 5 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,822 Underlying: Common Stock · 3,800 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 200 | $24.07 | $4,814.00 |
DisclosureSEC source: 0001209191-22-001849 · doc4.xml · nonDerivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,103 | $23.40 | $49,219.03 |
DisclosureSEC source: 0001209191-22-001849 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.03 to $23.83 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,497 | $22.47 | $33,633.10 |
DisclosureSEC source: 0001209191-22-001849 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,303 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.98 to $22.95 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 22:35 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 3,800 | $2.19 | $8,322.00 |
DisclosureSEC source: 0001209191-22-001849 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-067950 · doc4.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,622 Underlying: Common Stock · 5,700 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,500 | $25.06 | $62,656.00 |
DisclosureSEC source: 0001209191-21-067950 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.56 to $25.13 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,200 | $23.96 | $76,673.60 |
DisclosureSEC source: 0001209191-21-067950 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $24.42 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 01, 2021 Filed Dec 3, 2021 23:15 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-21-067950 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,900 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-062772 · doc4.xml · derivative · entry 7 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,322 Underlying: Common Stock · 1,900 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,900 | $25.00 | $47,500.00 |
DisclosureSEC source: 0001209191-21-062772 · doc4.xml · nonDerivative · entry 5 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 03, 2021 Filed Nov 3, 2021 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,900 | $2.19 | $4,161.00 |
DisclosureSEC source: 0001209191-21-062772 · doc4.xml · nonDerivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,800 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-062772 · doc4.xml · derivative · entry 6 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,222 Underlying: Common Stock · 3,800 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,610 | $23.72 | $38,195.16 |
DisclosureSEC source: 0001209191-21-062772 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.68 to $23.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 2,190 | $23.41 | $51,261.33 |
DisclosureSEC source: 0001209191-21-062772 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,610 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.67 to $23.66 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 3, 2021 22:05 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 3,800 | $2.19 | $8,322.00 |
DisclosureSEC source: 0001209191-21-062772 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:51 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-059111 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,022 Underlying: Common Stock · 5,700 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:51 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,700 | $24.83 | $141,505.92 |
DisclosureSEC source: 0001209191-21-059111 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.42 to $25.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 01, 2021 Filed Oct 4, 2021 21:51 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-21-059111 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 22:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-054552 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,722 Underlying: Common Stock · 5,700 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 22:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,700 | $26.00 | $148,222.80 |
DisclosureSEC source: 0001209191-21-054552 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.68 to $26.49 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 22:30 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-21-054552 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 23:41 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-049793 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,422 Underlying: Common Stock · 5,700 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 23:41 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,700 | $28.87 | $164,554.44 |
DisclosureSEC source: 0001209191-21-049793 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.68 to $29.32 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 23:41 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-21-049793 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:41 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,700 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-045097 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,122 Underlying: Common Stock · 5,700 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:41 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 5,700 | $33.33 | $189,986.70 |
DisclosureSEC source: 0001209191-21-045097 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.03 to $33.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:41 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 5,700 | $2.19 | $12,483.00 |
DisclosureSEC source: 0001209191-21-045097 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:48 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 575 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-21-037839 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,822 Underlying: Common Stock · 575 shares Expires 2028-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 21:48 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 575 | $39.43 | $22,669.49 |
DisclosureSEC source: 0001209191-21-037839 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.17 to $39.70 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.